研究人员扩大对多发性硬化症进展形式的关注：确定疾病起始的努力可能会为治疗提供线索。
Researchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment.
作者信息
Worley Susan
出版信息
P T. 2015 Sep;40(9):584-605.
Abstract
With disease-modifying treatments available for relapsing-remitting multiple sclerosis (MS), the quest for therapies for progressive MS has become a key focus of research.
摘要
随着针对复发缓解型多发性硬化症（MS）的疾病修正治疗方法的出现，寻找进行性MS的治疗方法已成为研究的关键重点。
相似文献
1
2
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
3
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.米托蒽醌治疗复发缓解型和快速进展型多发性硬化症：米托蒽醌治疗后十年的临床结果
Mult Scler Relat Disord. 2020 Sep;44:102330. doi: 10.1016/j.msard.2020.102330. Epub 2020 Jun 23.
4
Rituximab for relapsing-remitting multiple sclerosis.利妥昔单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
5
Siponimod for the treatment of secondary progressive multiple sclerosis.西尼莫德用于治疗继发进展型多发性硬化。
Expert Opin Pharmacother. 2019 Feb;20(2):143-150. doi: 10.1080/14656566.2018.1551363. Epub 2018 Dec 5.
6
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.多发性硬化症高效疾病修正疗法的排序：观点与方法
Neural Regen Res. 2018 Nov;13(11):1871-1874. doi: 10.4103/1673-5374.239432.
7
The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.多发性硬化症的表现似乎较轻：诊断标准、治疗方法和自然病程的变化。
Brain. 2020 Sep 1;143(9):2637-2652. doi: 10.1093/brain/awaa145.
8
Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?索尼娅·斯利夫卡研究参与者使用疾病修饰疗法的情况及成本：自2000年和2009年以来真的有什么变化吗？
Mult Scler J Exp Transl Clin. 2019 Feb 20;5(1):2055217318820888. doi: 10.1177/2055217318820888. eCollection 2019 Jan-Mar.
9
Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.复发缓解型多发性硬化症和继发进展型多发性硬化症中的脑萎缩：纵向定量分析
Radiology. 2000 Mar;214(3):665-70. doi: 10.1148/radiology.214.3.r00mr30665.
10
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.疾病修正治疗药物（DMD）对继发进展型多发性硬化的发生有积极影响吗？评论。
Rev Neurol (Paris). 2020 Jun;176(6):500-504. doi: 10.1016/j.neurol.2020.03.005. Epub 2020 Apr 8.
本文引用的文献
1
Identifying responders and nonresponders to interferon therapy in multiple sclerosis.识别多发性硬化症中干扰素治疗的应答者和无应答者。
Degener Neurol Neuromuscul Dis. 2014 Apr 1;4:75-85. doi: 10.2147/DNND.S42734. eCollection 2014.
2
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.一项遗传药理学研究表明 SLC9a9 与多发性硬化症的疾病活动有关。
Ann Neurol. 2015 Jul;78(1):115-27. doi: 10.1002/ana.24429. Epub 2015 May 14.
3
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.基于钆的磁共振成像对多发性硬化软脑膜炎症的特征分析
Neurology. 2015 Jul 7;85(1):18-28. doi: 10.1212/WNL.0000000000001587. Epub 2015 Apr 17.
4
PML in a patient with lymphocytopenia treated with dimethyl fumarate.一名淋巴细胞减少症患者在接受富马酸二甲酯治疗后发生进行性多灶性白质脑病。
N Engl J Med. 2015 Apr 9;372(15):1476-8. doi: 10.1056/NEJMc1415408.
5
Alemtuzumab for the treatment of multiple sclerosis.阿仑单抗用于治疗多发性硬化症。
Ther Clin Risk Manag. 2015 Mar 31;11:525-34. doi: 10.2147/TCRM.S80112. eCollection 2015.
6
No quiet surrender: molecular guardians in multiple sclerosis brain.绝不轻易屈服：多发性硬化症大脑中的分子守护者
J Clin Invest. 2015 Apr;125(4):1371-8. doi: 10.1172/JCI74255. Epub 2015 Apr 1.
7
Patients report worse MS symptoms after menopause: findings from an online cohort.患者报告绝经后多发性硬化症状加重：一项在线队列研究的结果
Mult Scler Relat Disord. 2015 Jan;4(1):18-24. doi: 10.1016/j.msard.2014.11.009. Epub 2014 Dec 9.
8
Pathological mechanisms in progressive multiple sclerosis.进行性多发性硬化症的病理机制。
Lancet Neurol. 2015 Feb;14(2):183-93. doi: 10.1016/S1474-4422(14)70256-X.
9
Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic.药物整合应激反应增强可保护少突胶质细胞，并为多发性硬化症提供一种潜在的治疗方法。
Nat Commun. 2015 Mar 13;6:6532. doi: 10.1038/ncomms7532.
10
Multiple sclerosis-a quiet revolution.多发性硬化症——一场悄然的变革。
Nat Rev Neurol. 2015 Mar;11(3):134-42. doi: 10.1038/nrneurol.2015.14. Epub 2015 Feb 17.
Zotero 插件